Lebang Pharmaceutical-B (09637) public offering received nearly a thousand times oversubscribed and will debut on the Hong Kong Stock Exchange on June 29.

Li Bang Pharmaceuticals-B (09637) announced the results of the placement, showing that the Hong Kong public offering was significantly oversubscribed, with a subscription ratio of approximately 963.56 times; the international offering also received about 19.77 times subscription, indicating a high level of market interest. The company's H shares will be officially listed on the Hong Kong Stock Exchange on June 29, with the stock code 09637 and 100 shares per board lot. The announcement stated that Li Bang Pharmaceuticals-B's global offering this time was 56.7554 million H shares, with 5.6756 million shares offered in Hong Kong and 51.0798 million shares offered internationally. The offering price was set at HK$22.60 per share, with net proceeds of approximately HK$1.1808 billion. The Hong Kong public offering received a total of 145,729 applications, with 35,131 accepted and a 6% lottery rate. It is worth noting that the company introduced cornerstone investors in this offering, including GIC, Loomis Sayles, RTW Fund, Symbiosis, Tencent, Cormorant, DAMSIMF, GF Fund, Huatai Hong Kong, E Fund, and LVC. The cornerstone investors collectively received 28.2549 million shares, and based on the non-exercise of their additional share allocation rights, they accounted for approximately 49.78% of the global offering shares and approximately 8.31% of the total share capital after listing.